27.3 C
New York

covaxin: WHO finally grants Emergency Use Listing to Covaxin | India News

Published:


HYDERABAD: After dithering for weeks, the World Health Organization (WHO) finally granted emergency use listing (EUL) to India’s first indigenously developed Covid-19 vaccine, Covaxin, on Wednesday.
The approval comes as a major respite to millions of Indians who have been vaccinated with the inactivated virus vaccine but were facing restrictions in travelling abroad. Now those who have received two doses of Covaxin can travel abroad without having to undergo quarantine.
“WHO has granted emergency use listing (EUL) to #COVAXIN (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #Covid19,” the global health body tweeted on Wednesday evening.
The nod came after WHO’s technical advisory group (TAG) met again on Wednesday to conduct a final risk-benefit analysis of the vaccine after its earlier meeting on October 26.
WHO’s strategic advisory group of experts on immunisation (SAGE) had met on October 5 to recommend the vaccine. However, after tweeting on October 5 that it would take a final call on Covaxin the week after, WHO had been putting off granting the approval citing lack of clarity on certain aspects pertaining to the vaccine.
Covaxin’s developer Bharat Biotech had submitted its expression of interest on April 19 this year and the rolling data submission began on July 6.
The vaccine demonstrated a 77.8% efficacy against symptomatic Covid-19 and 65.2% efficacy against the deadly Delta variant that was first detected in India and has now emerged as the dominant variant globally. The Phase-3 trials were conducted on nearly 26,000 people in India.
Covaxin has been a part of India’s national immunisation programme even while its Phase-3 trials were underway after it was granted emergency use authorisation (EUA) by the Indian drug regulator on January 3.



Denial of responsibility! - If you are a regular visitor then ignore this...
Read Full Details



**If you have any Query Related This Post then here is the Source Link**

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Recent articles